Instrumentation Metrics' Noninvasive Glucose Monitor Pivotal Study Planned
This article was originally published in The Gray Sheet
Instrumentation Metrics will complete a clinical trial later in March for its IM200 noninvasive glucose monitor in anticipation of a 300 to 400-patient, multi-center pivotal study. The Chandler, Arizona firm plans to submit a premarket approval application for the device in late 2002 or early 2003.
You may also be interested in...
SonoSite: Handheld digital ultrasound device manufacturer plans secondary offering of 2.7 mil. shares of common stock. Assuming a public offering price of $22.95 per share, estimated net proceeds would be about $57.8 mil., according to a Feb. 22 prospectus filed with the Securities and Exchange Commission. The funds will be used for general corporate purposes, which may include expanded sales and marketing efforts for the SonoSite 180Plus and SonoHeart Elite ultrasound devices, as well as expanded manufacturing, R&D and potential acquisitions, SonoSite says. The Bothell, Washington firm has granted managing underwriters UBS Warburg and Deutsche Banc Alex. Brown the option to purchase an additional 405,000 shares to cover any over allotments, which could boost net proceeds to $66.5 mil., according to SonoSite...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.